Detection of developmental toxicity of the anti-COVID-19 drug molnupiravir using gastruloid-based in vitro assays
et al., Toxicological Sciences, doi:10.1093/toxsci/kfaf093, Jul 2025
In vitro study showing developmental toxicity with N4-hydroxycytidine (NHC), the active metabolite of molnupiravir, in mouse and human gastruloid models. Authors exposed P19C5 mouse embryonic-stem-cell gastruloids to 20 µM NHC, which severely impeded axial elongation and disrupted developmental gene programs. Human embryonic-stem-cell gastruloids manifested aggregate-size reduction at 10 µM and significant transcriptional changes from 2.5 µM. All toxic concentrations overlap the ~10.8 µM plasma Cmax reached in patients at the authorized molnupiravir dose. By showing teratogenic signals previously seen in animal studies while eliminating live-animal use, the gastruloid assay shows value as a rapid, human-relevant screen for antiviral developmental toxicity.
Potential risks of molnupiravir include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity1-15. Multiple analyses have identified variants potentially created by molnupiravir16-20.
1.
Swanstrom et al., Lethal mutagenesis as an antiviral strategy, Science, doi:10.1126/science.abn0048.
2.
Hadj Hassine et al., Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity, Viruses, doi:10.3390/v14040841.
3.
Shum, C., An investigational study into the drug-associated mutational signature in SARS-CoV-2 viruses, The University of Hong Kong, PhD Thesis, hub.hku.hk/handle/10722/344396.
4.
Waters et al., Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir, Environmental and Molecular Mutagenesis, doi:10.1002/em.22471.
5.
Huntsman, M., An assessment of the reproductive toxicity of the anti-COVID-19 drug molnupiravir using stem cell-based embryo models, Master's Thesis, scholarspace.manoa.hawaii.edu/items/cd11342c-b4dc-44c0-8b44-ce6e3369c40b.
6.
Huntsman (B) et al., Detection of developmental toxicity of the anti-COVID-19 drug molnupiravir using gastruloid-based in vitro assays, Toxicological Sciences, doi:10.1093/toxsci/kfaf093.
7.
Zibat et al., N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody, iScience, doi:10.1016/j.isci.2023.107786.
8.
Shiraki et al., Convenient screening of the reproductive toxicity of favipiravir and antiviral drugs in Caenorhabditis elegans, Heliyon, doi:10.1016/j.heliyon.2024.e35331.
9.
Gruber et al., Molnupiravir increases SARS‐CoV‐2 genome diversity and complexity: A case‐control cohort study, Journal of Medical Virology, doi:10.1002/jmv.29642.
10.
Marikawa et al., An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations, Reproductive Toxicology, doi:10.1016/j.reprotox.2023.108475.
11.
Rahman, M., Elucidation of the DNA repair mechanisms involved in the repair of DNA damage caused by the Arabinosides and Anti-COVID-19 drugs, tokyo-metro-u.repo.nii.ac.jp/records/2000972.
12.
Zhou et al., β-D-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells, The Journal of Infectious Diseases, doi:10.1093/infdis/jiab247.
13.
Chamod et al., Molnupiravir Metabolite--N4-hydroxycytidine Causes Cytotoxicity and DNA Damage in Mammalian Cells in vitro: N4-hydroxycytidine Induced Cytotoxicity DNA Damage, Asian Medical Journal and Alternative Medicine, 23:3, asianmedjam.com/index.php/amjam/article/view/1448.
14.
Standing et al., Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients, Nature Communications, doi:10.1038/s41467-024-45641-0.
15.
Mori et al., Reactive oxygen species-mediated cytotoxic and DNA-damaging mechanism of N4-hydroxycytidine, a metabolite of the COVID-19 therapeutic drug molnupiravir, Free Radical Research, doi:10.1080/10715762.2025.2469738.
16.
Focosi et al., The fitness of molnupiravir-signed SARS-CoV-2 variants: imputation analysis based on prescription counts and GISAID analyses by country, Intervirology, doi:10.1159/000540282.
17.
Sanderson et al., A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes, Nature, doi:10.1038/s41586-023-06649-6.
18.
Fountain-Jones et al., Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study, The Lancet Microbe, doi:10.1016/S2666-5247(23)00393-2.
Huntsman et al., 22 Jul 2025, peer-reviewed, 2 authors.
In vitro studies are an important part of preclinical research, however results may be very different in vivo.
DOI record:
{
"DOI": "10.1093/toxsci/kfaf093",
"ISSN": [
"1096-6080",
"1096-0929"
],
"URL": "https://doi.org/10.1093/toxsci/kfaf093",
"abstract": "<jats:title>Abstract</jats:title>\n <jats:p>In pharmaceutical drug development, animal tests are traditionally required to conduct comprehensive toxicity assessments before initiating human clinical trials. However, animal tests are time-consuming and can hinder the rapid development of drugs needed to combat urgent health crises, such as the COVID-19 pandemic. Therefore, faster non-animal alternatives are critical to accelerating preclinical toxicity assessments. Molnupiravir, an antiviral medication authorized for emergency use to treat COVID-19, is an oral pro-drug that is metabolized into its active form, N4-hydroxycytidine (NHC). The developmental toxicity of molnupiravir was initially identified in preclinical animal studies. The present study aims to determine whether in vitro assays using gastruloids–three-dimensional aggregates of pluripotent stem cells that mimic axial elongation morphogenesis of early embryos–can effectively detect the developmental toxicity of molnupiravir in a clinically relevant context. In our experiments, NHC at 20 μM significantly impaired the morphological progression and altered the gene expression profiles in gastruloids derived from mouse P19C5 stem cells. Similarly, in a human embryonic stem cell-based morphogenesis model, NHC reduced the aggregate size at 10 μM and induced significant gene expression changes at concentrations as low as 2.5 μM. Notably, these NHC concentrations are comparable to the plasma levels observed in humans (approximately 10.8 μM) following administration of the clinically recommended dose of molnupiravir. These findings demonstrate that gastruloid-based assays can reliably detect the developmental toxicity of NHC at clinically relevant concentrations, supporting their utility as non-animal tools for expediting preclinical developmental toxicity assessments.</jats:p>",
"article-number": "kfaf093",
"author": [
{
"affiliation": [
{
"name": "University of Hawaii John A. Burns School of Medicine Yanagimachi Institute for Biogenesis Research, Department of Anatomy, Biochemistry and Physiology, , Honolulu, HI, 96813,",
"place": [
"USA"
]
}
],
"family": "Huntsman",
"given": "Margaret Carrell",
"sequence": "first"
},
{
"ORCID": "https://orcid.org/0000-0001-5720-5806",
"affiliation": [
{
"name": "University of Hawaii John A. Burns School of Medicine Yanagimachi Institute for Biogenesis Research, Department of Anatomy, Biochemistry and Physiology, , Honolulu, HI, 96813,",
"place": [
"USA"
]
}
],
"authenticated-orcid": false,
"family": "Marikawa",
"given": "Yusuke",
"sequence": "additional"
}
],
"container-title": [
"Toxicological Sciences"
],
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2025,
7,
19
]
],
"date-time": "2025-07-19T11:56:20Z",
"timestamp": 1752926180000
},
"deposited": {
"date-parts": [
[
2025,
7,
22
]
],
"date-time": "2025-07-22T04:24:34Z",
"timestamp": 1753158274000
},
"indexed": {
"date-parts": [
[
2025,
7,
22
]
],
"date-time": "2025-07-22T04:40:07Z",
"timestamp": 1753159207059,
"version": "3.41.2"
},
"is-referenced-by-count": 0,
"issn-type": [
{
"type": "print",
"value": "1096-6080"
},
{
"type": "electronic",
"value": "1096-0929"
}
],
"issued": {
"date-parts": [
[
2025,
7,
22
]
]
},
"language": "en",
"license": [
{
"URL": "https://academic.oup.com/pages/standard-publication-reuse-rights",
"content-version": "am",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2025,
7,
22
]
],
"date-time": "2025-07-22T00:00:00Z",
"timestamp": 1753142400000
}
}
],
"link": [
{
"URL": "https://academic.oup.com/toxsci/advance-article-pdf/doi/10.1093/toxsci/kfaf093/63814434/kfaf093.pdf",
"content-type": "application/pdf",
"content-version": "am",
"intended-application": "syndication"
},
{
"URL": "https://academic.oup.com/toxsci/advance-article-pdf/doi/10.1093/toxsci/kfaf093/63814434/kfaf093.pdf",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "286",
"original-title": [],
"prefix": "10.1093",
"published": {
"date-parts": [
[
2025,
7,
22
]
]
},
"published-online": {
"date-parts": [
[
2025,
7,
22
]
]
},
"publisher": "Oxford University Press (OUP)",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "https://academic.oup.com/toxsci/advance-article/doi/10.1093/toxsci/kfaf093/8210082"
}
},
"score": 1,
"short-container-title": [],
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": [
"Detection of developmental toxicity of the anti-COVID-19 drug molnupiravir using gastruloid-based in vitro assays"
],
"type": "journal-article"
}